Loading company
$3.220.0%Nov 6 close
Reported results on October 29, 2026; they are not in these figures yet.
Figures through December 31, 2025, from the 20-F filed March 12, 2026
Past performance
- 1M
- -11.9%
- 3M
- -23.6%
- 6M
- -16.3%
- 1Y
- -23.8%
- 5Y
- -78.2%
$3.220.0%Nov 6 close
Reported results on October 29, 2026; they are not in these figures yet.
Figures through December 31, 2025, from the 20-F filed March 12, 2026
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toMar 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $3.3M | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“This third quarter marked a decisive step in Molecular Partners’ transformation into a dedicated radiopharmaceuticals company. Encouraged by the emerging Phase 1/2a data from MP0712, our DLL3 Radio-DARPin for SCLC, we believe now is the time to focus on targeted radiotherapy. With efficacy data expected in 2027, we will continue to execute our lead asset MP0712 and advance our clinical Radio-DARPin programs to deliver value to shareholders and meaningful benefit to cancer patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeuti cs for cancer patients underserved by existing treatment modalities. Molecular Partners focuses on the development of targeted radiotherapeutics, leveraging the unique properties of DARPin miniproteins as isotope-agnostic vector. The Company’s lead medicine MP0712, targeting DLL3 and armed with 212 Pb, advances in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers. Molecular Partners has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Molecular Partners AG filed on October 29, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Molecular Partners AG has no earnings call transcript available.